Kanaoka T et al. – These results show that aliskiren, as a first–line regimen, improves the ambulatory blood pressure (BP) profile and may have protective vascular effects in Japanese nondiabetic patients with untreated mild to moderate essential hypertension.
- Aliskiren is a direct renin inhibitor that exerts its effect at the rate–limiting step of the renin–angiotensin system.
- This study was performed to examine the beneficial effects of aliskiren–based antihypertensive therapy on the ambulatory blood pressure (BP) profile, central hemodybamics, and arterial stiffness in untreated Japanese patients with mild to moderate hypertension.
- 21 Japanese nondiabetic patients with untreated mild to moderate essential hypertension were initially given aliskiren once daily at 150 mg, and the dose was titrated up to 300 mg as needed.
- After 12 weeks of aliskiren–based therapy, the clinic, ambulatory, and central BP values as well as brachial–ankle pulse wave velocity (baPWV) were all significantly decreased compared with baseline (clinic systolic BP, 151±11 mm Hg vs 132±11 mm Hg; clinic diastolic BP, 91±13 mm Hg vs 82±9 mm Hg; 24–hour systolic BP, 144±12 mm Hg vs 133±11 mm Hg; 24–hour diastolic BP, 88±8 mm Hg vs 81±9 mm Hg; central BP, 162±16 mm Hg vs 148±14 mm Hg; baPWV, 1625±245 cm/s vs 1495±199 cm/s; P<.05).